Back to Newsroom

Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results

Conference Call Scheduled May 11, 2017 at 4:30 p.m. EDT

BERKELEY HEIGHTS, N.J., May 11, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel” or the “Company”) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the first quarter ended March 31, 2017.